Pharmacology expert, Dr. Gobind Rai Garg has come up with a comprehensive list of new drugs approved in 2019. The table includes the name of the drug, mechanism, route, and indication.

This list will prove helpful to you for the upcoming competitive exams.

Champion's Blueprint: A Result Oriented Approach to PG Prep

Enroll Now »

 

FDA-APPROVED DRUGS IN 2019

Drug

Mechanism

Route

Indication

Afamelanotide

Melanocortin 1 receptor agonist

Subcutaneous

Phototoxicity in patients with erythropoieticprotoporphyria

Alpelisib

PI3 kinase inhibitor

Oral

Breast cancer

Amifampridine

K channel blocker

Oral

Lambert Eaton Myasthenic syndrome

Andexanet alpha

Bind to Factor Xa inhibitors

Intravenous

To reverse overdose of rivaroxaban and apixaban

Apalutamide

Darolutamide

Androgen receptor antagonist

Oral

Prostate carcinoma

Apremilast

PDE-4 inhibitor

Oral

Oral ulcers associated with Behcet disease

Atezolizumab

MAb against PDL-1

IV

Extensive stage-Small Cell Lung Cancer

Avatrombopag

Lusutrombopag

Thrombopoietin receptor agonist

Oral

Thrombocytopenia in patients with chronic liver disease

Avelumab + Axitinib

Avelumab: Anti-PDL-1

Axitinib: anti-VEGF kinase

Avelumab: IV

Axitinib: Oral

Renal cell carcinoma

Baloxavirmarboxil

Inhibit viral replication by inhibiting Cap-dependent endonuclease activity of viral polymerase

Oral

Single dose treatment of Acute uncomplicated influenza

Baricitinib

Janus Kinase inhibitor

Oral

Rheumatoid Arthritis

Bictegravir

Integrase inhibitor

Oral

HIV

Binimetinib

MET tyrosine kinase inhibitor

Oral

BRAF V600E or V600K mutation-positive malignant melanoma

Bremelanotide

Melanocortin receptor agonist

subcutaneous

Hypoactive sexual desire disorder in females

Brexanolone

GABA-A modulator

Intravenous

Post partum depression

Brolucizumab

VEGF inhibitor

Intravitreal

Neovascular Age Related Macular Degeneration

Burosumab

Monoclonal antibody against FGF-23

Subcutaneous

X-linked hypophosphatemia

Calaspargasepegol

Asparagine specific enzyme

Intravenous

Acute lymphocytic leukemia

Cannabidiol

Unknown

Oral

Lennox Gastaut syndrome

Dravet Syndrome

Caplacizumab

vWF-directed antibody fragment

IV/SC

Thrombotic Thrombocytopenic Purpura

Cemiplimab

Monoclonal antibody against Programmed Death receptor (PD-1)

Intravenous

Squamous cell carcinoma of skin

Cenegermin

Recombinant human nerve growth factor

Eye drops

Neurotrophic keratitis

Dacomitinib

EGFR tyrosine kinase inhibitor

Oral

Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations

Diroximelfumarate

Forms monomethylfumarate

Oral

Multiple sclerosis

Doravirine

Non-nucleoside Reverse Transcriptase Inhibitor

Oral

HIV

Dupilumab

MAb against IL-4R alpha. It stops signaling of IL-4 and IL-13

SC

Chronic rhinosinusitis with nasal polyposis

Duvelisib

 

Inhibitor of PI-3 kinase gamma and delta

Oral

Small lymphocytic lymphoma

Follicular lymphoma

Chronic lymphoid leukemia

Elagolix

 

GnRH antagonist

Oral

Pain associated with endometriosis

Elapegademase

Recombinant Adenosine deaminase enzyme

Intramuscular

Adenosine Deaminase-Severe Combined Immunodeficiency

Emapalumab

Monoclonal antibody against IFN-gamma

Intravenous

Primary hemophagocyticlymphohistiocytosis

Encorafenib

 

BRAF-Kinase Inhibitor

Oral

BRAF V600E or V600K mutation-positive malignant melanoma

Entrectinib

Tyrosine kinase inhibitor of ROS-1 and NTRK

Oral

ROS-1 positive Non smallcell lung cancer and NRTK positive solid tumors

Eravacycline

 

Inhibit protein synthesis like other tetracyclines

Intravenous

Complicated intra-abdominal infections

Erdafitinib

FGFR Tyrosine kinase inhibitor

Oral

Urothelial carcinoma

Erenumab

Fremanezumab

Galcanezumab

Monoclonal antibody against CGRP

SC

Migraine prophylaxis

Esketamine

Non-competitive NMDA antagonist

Intranasal

Treatment resistant depression

Fedratinib

JAK-2 Inhibitor

Oral

Myelofibrosis

Fostamatinib disodium hexahydrate

Spleen tyrosine kinase inhibitor

Oral

ITP

Gilteritinib

FLT3 kinase inhibitor

Oral

Acute myeloid leukemia

Glasdegib

Hedgehog pathway inhibitor

Oral

Acute myeloid leukemia

Ibalizumab

MAb against CD4

IV

HIV

Inotersen

Antisense oligonucleotide against transthyretin mRNA

Subcutaneous

Polyneuropathy of hereditary transthyretin-mediated amyloidosis

Istradefylline

Adenosine A2 receptor antagonist

Oral

Off episode in Parkinsonism

Ivosidenib

 

Isocitrate dehydrogenase 2 (IDH2) inhibitor

Oral

Acute myeloid leukemia with IDH2 mutation

Ixekizumab

MAb against IL-17a

Subcutaneous

Ankylosing Spondylitis

Lanadelumab

 

Monoclonal antibody against plasma kallikrein

Subcutaneous

Hereditary Angioneurotic Edema

Larotrectinib

NTRK kinase inhibitor

Oral

Solid tumors with NTRK mutation

Lasmiditan

5HT1F agonist

Oral

Acute severe migraine

Lefamulin

Inhibit protein synthesis in bacteria

IV and oral

Community acquired bacterial pneumonia

Lenvatinib

VEGFR tyrosine kinase inhibitor

Oral

Endometrial carcinoma (with pembrolizumab)

Lofexidine

Alpha 2 agonist

Oral

To decrease opioid withdrawal symptoms

Lorlatinib

ALK kinase inhibitor

Oral

Non small cell carcinoma of lung

Lutetium lu 177 dotatate

 

Peptide receptor radionuclide therapy

Intravenous

Gastro-entero-pancreatic neuroendocrine tumors

Megalastat

 

Pharmacological chaperone for Alpha galactosidase

Oral

Fabry’s disease

Mogamulizumab

 

Monoclonal antibody against CCR-4

Intravenous

Mycosis fungoides

Sezary syndrome

Moxetumomabpasudutox

 

Monoclonal antibody against CD22 conjugated with Pseudomonas exotoxin

Intravenous

Hairy cell leukemia

Moxidectin

 

Bind to Glutamate and GABA chloride channels

Oral

Onchocerciasis

Netarsudil + Latanoprost

Netarsudil: Rho kinase inhibitor

Latanoprost: PGF2 apha

Topical

Open angle glaucoma

Nintedanib

Tyrosine kinase inhibitor of PDGFR, VEGFR, FGF, FLT-3

Oral

To slow decline in pulmonary function in systemic sclerosis associated with Intersitial lung disease

Omadacycline

 

Inhibit protein synthesis like other tetracyclines

Oral

Intravenous

Community acquired bacterial pneumonia

Acute skin and skin structure infections

Onasemnogeneabeparvovec

AAV vector based gene therapy to transfer SMN gene

Intravenous

Spinal muscular atrophy

Patisiran

 

Small Interfering RNA based therapy against mutant transthyretin

Intravenous

Polyneuropathy in patients with transthyretin mediated amyloidosis

Pegvaliase

Substitute of Phenylalanine hydroxylase

SC

Phenylketonuria

Pembrolizumab

MAb against PD-1

IV

Endometrial carcinoma (with lenvatinib)

Esophageal cancer

Small cell lung cancer

Non small cell lung cancer

Renal cell carcinoma

Pexidartinib

TK inhibitor of Colony Stimulating Factor 1 Receptor

Oral

Tenosynovial Giant Cell Tumor

Pitolisant

H3 antagonist/inverse agonist

Oral

Narcolepsy

Plazomicin

 

Inhibit protein synthesis like other aminoglycosides

Intravenous

Complicated UTI

Polatuzumabvedotin

MAb against C79b component of B cell receptor

Intravenous

Diffuse large B cell lymphoma

Prabotulinum toxin-A

Inhibit release of ACh

Intramuscular

Temporary improvement of glabellar lines

Pretomanid

Inhibit mycolic acid synthesis

Oral

For XDR and MDR TB (in combination with bedaquiline and linezolide)

Prucalopride

5HT4 agonist

Oral

Chronic Idiopathic Constipation

Ramucirumab

VEGF antagonist

Intravenous

Hepatocellular carcinoma

Ravulizumab

C5 Complement inhibitor

Intravenous

Paroxysomal Nocturnal Hemoglobinuria

Relebactam

Beta lactamase inhibitor

Intravenous

In combination with imipenem and cilastatin for intraabdominal infections and UTI

Revefenacin

Anticholinergic

Inhalational

COPD

Rifamycin

Inhibit beta subunit of RNA polymerase

Oral

Traveller’s diarrhea

Rimabotulinumtoxin B

Inhibits release of acetylcholine

Injected in salivary glands

Chronic siallorhea

Risankizumab

MAb against IL-23

Subcutaneous

Plaque psoriasis

Romosozumab

MAb against sclerostin

Subcutaneous

Post-menopausal osteoporosis

Ruxolitinib

JAK-1 and JAK-2 inhibitor

Oral

Steroid resistant acute graft vs host disease

Sarecycline

 

Inhibit protein synthesis like other tetracyclines

Oral

Inflammatory lesions of non-nodular moderate to severe acne

Segesterone  + ethinyl estradiol

Inhibit ovulation

Vaginal ring

Contraception (once yearly)

Selinexor

Selective inhibitor of nuclear export

Oral

Multiple myeloma

Diffuse large B cell lymphoma

Semaglutide

GLP-1 agonist

Oral

Type 2 diabetes mellitus

Siponimod

Sphingosine-1 phsophate receptor modulator

Oral

Multiple sclerosis

Sodium zirconium cyclosilicate

Binds to K and increase fecal excretion

oral

Hyperkalemia

Solriamfetol

DA and NA reuptake inhibitor

Oral

For excessive day time sleepiness in Obstructive sleep apnea and Narcolepsy

Stiripentol

 

Increases GABAergic activity

Oral

Dravet Syndrome

Tafamidismeglumine

Act as chaperone to stabilize TTR protein

Oral

To prevent cardiomyopathy in TTR amyloidosis

Tafenoquine

Free radical mediated killing of hypnozooites

Oral

Single dose radical cure of P. vivax malaria

Tagraxofusp

Anti-CD-123

Intravenous

BlasticPlasmacytoid Dendritic Cell Neoplasm

Talazoparib

PARP inhibitor

Oral

breast cancer with a germline BRCA mutation

Tecovirimat

 

Inhibit formation of extracellular viral forms

Oral

Small pox

Tenapanor

NHE-3 inhibitor

Oral

IBS with constipation

Tildrakizumab

MAb against IL-23

SC

Plaque Psoriasis

Tizacaftor + ivacaftor

CFTR  stimulator and potentiator

Oral

Cystic fibrosis

Tolvaptan

Vasopressin V2 receptor antagonist

Oral

To slow kidney function decline in adult polycystic kidney disease

Trifarotene

Retinoic acid receptor agonist

Topical

Acne vulgaris

Upadacitinib

JAK inhibitor

Oral

Rheumatoid Arthritis

Venetoclax + Obinutuzumab

Venetoclax: BCL-2 inhibitor

Obinutuzumab: Binds to CD-20 on B cells

Venetoclax: Oral

Obintuzumab: IV

Chronic lymphoid leukemia

Small lymphocytic leukemia

 

Good Luck!

Keep Following PrepLadder for more updates!!

Download the New PrepLadder App